154 related articles for article (PubMed ID: 12941325)
1. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
[TBL] [Abstract][Full Text] [Related]
2. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
[TBL] [Abstract][Full Text] [Related]
3. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
4. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.
Misra RN; Xiao Hy; Rawlins DB; Shan W; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
Bioorg Med Chem Lett; 2003 Jul; 13(14):2405-8. PubMed ID: 12824044
[TBL] [Abstract][Full Text] [Related]
5. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.
Hamdouchi C; Keyser H; Collins E; Jaramillo C; De Diego JE; Spencer CD; Dempsey JA; Anderson BD; Leggett T; Stamm NB; Schultz RM; Watkins SA; Cocke K; Lemke S; Burke TF; Beckmann RP; Dixon JT; Gurganus TM; Rankl NB; Houck KA; Zhang F; Vieth M; Espinosa J; Timm DE; Campbell RM; Patel BK; Brooks HB
Mol Cancer Ther; 2004 Jan; 3(1):1-9. PubMed ID: 14749470
[TBL] [Abstract][Full Text] [Related]
6. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
7. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
8. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
Byth KF; Culshaw JD; Green S; Oakes SE; Thomas AP
Bioorg Med Chem Lett; 2004 May; 14(9):2245-8. PubMed ID: 15081017
[TBL] [Abstract][Full Text] [Related]
9. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
[TBL] [Abstract][Full Text] [Related]
10. 6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).
Witherington J; Bordas V; Gaiba A; Naylor A; Rawlings AD; Slingsby BP; Smith DG; Takle AK; Ward RW
Bioorg Med Chem Lett; 2003 Sep; 13(18):3059-62. PubMed ID: 12941333
[TBL] [Abstract][Full Text] [Related]
11. Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.
Tang J; Shewchuk LM; Sato H; Hasegawa M; Washio Y; Nishigaki N
Bioorg Med Chem Lett; 2003 Sep; 13(18):2985-8. PubMed ID: 12941317
[TBL] [Abstract][Full Text] [Related]
12. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
[TBL] [Abstract][Full Text] [Related]
13. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
14. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
16. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2).
Yue EW; Higley CA; DiMeo SV; Carini DJ; Nugiel DA; Benware C; Benfield PA; Burton CR; Cox S; Grafstrom RH; Sharp DM; Sisk LM; Boylan JF; Muckelbauer JK; Smallwood AM; Chen H; Chang CH; Seitz SP; Trainor GL
J Med Chem; 2002 Nov; 45(24):5233-48. PubMed ID: 12431051
[TBL] [Abstract][Full Text] [Related]
19. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS; Kimball SD; Misra RN; Rawlins DB; Hunt JT; Xiao HY; Lu S; Qian L; Han WC; Shan W; Mitt T; Cai ZW; Poss MA; Zhu H; Sack JS; Tokarski JS; Chang CY; Pavletich N; Kamath A; Humphreys WG; Marathe P; Bursuker I; Kellar KA; Roongta U; Batorsky R; Mulheron JG; Bol D; Fairchild CR; Lee FY; Webster KR
J Med Chem; 2002 Aug; 45(18):3905-27. PubMed ID: 12190313
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Beattie JF; Breault GA; Ellston RP; Green S; Jewsbury PJ; Midgley CJ; Naven RT; Minshull CA; Pauptit RA; Tucker JA; Pease JE
Bioorg Med Chem Lett; 2003 Sep; 13(18):2955-60. PubMed ID: 12941311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]